JonesTrading downgraded shares of Sionna Therapeutics (NASDAQ:SION – Free Report) from a strong-buy rating to a hold rating in a research note issued to investors on Monday,Zacks.com reports.
A number of other research analysts also recently issued reports on the stock. BTIG Research downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. Citizens Jmp cut shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. Citigroup downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Stifel Nicolaus reiterated a “hold” rating and set a $7.00 price objective on shares of Sionna Therapeutics in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sionna Therapeutics presently has a consensus rating of “Hold” and an average price target of $42.22.
View Our Latest Research Report on SION
Sionna Therapeutics Stock Performance
Sionna Therapeutics (NASDAQ:SION – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, research analysts predict that Sionna Therapeutics will post -2.66 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Peter A. Thompson sold 115,844 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 403,726 shares of company stock worth $18,259,354 over the last ninety days. 5.10% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in SION. UBS Group AG raised its holdings in shares of Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares during the last quarter. Vanguard Group Inc. boosted its stake in Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Jennison Associates LLC boosted its stake in Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Candriam S.C.A. bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $9,494,000. Finally, Eventide Asset Management LLC bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $26,290,000.
More Sionna Therapeutics News
Here are the key news stories impacting Sionna Therapeutics this week:
- Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
- Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
- Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
- Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
- Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails
Sionna Therapeutics Company Profile
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
